Sonolisib

N/A

Report date: 2022/09/23 20:01:17
NME

Base Information

Drug NameSonolisib
Drug Alias Name索诺利司sonolisibum索诺利塞DJM-166DJM-2-166 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitors
TargetsPI3-kinase class I
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCascadian Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCascadian Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A